

Paresh Dandona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5772240/publications.pdf>

Version: 2024-02-01

166
papers

17,273
citations

18482

62
h-index

13771

129
g-index

167
all docs

167
docs citations

167
times ranked

16535
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 2004, 25, 4-7.	6.8	1,812
2	Metabolic Syndrome. Circulation, 2005, 111, 1448-1454.	1.6	1,157
3	Insulin Inhibits Intranuclear Nuclear Factor κ B and Stimulates κ B in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3257-3265.	3.6	610
4	Circulating Mononuclear Cells in the Obese Are in a Proinflammatory State. Circulation, 2004, 110, 1564-1571.	1.6	576
5	Glucose Challenge Stimulates Reactive Oxygen Species (ROS) Generation by Leucocytes. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2970-2973.	3.6	549
6	Elevation of Free Fatty Acids Induces Inflammation and Impairs Vascular Reactivity in Healthy Subjects. Diabetes, 2003, 52, 2882-2887.	0.6	546
7	Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5462-5468.	3.6	546
8	Tumor Necrosis Factor- α in Sera of Obese Patients: Fall with Weight Loss. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2907-2910.	3.6	479
9	Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Receptors and Suppressor of Cytokine Signaling-3 in Mononuclear Cells After a High-Fat, High-Carbohydrate Meal. Diabetes Care, 2009, 32, 2281-2287.	8.6	426
10	Evidence for a Potent Antiinflammatory Effect of Rosiglitazone. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2728-2735.	3.6	355
11	The Suppressive Effect of Dietary Restriction and Weight Loss in the Obese on the Generation of Reactive Oxygen Species by Leukocytes, Lipid Peroxidation, and Protein Carbonylation ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 355-362.	3.6	308
12	Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. Diabetes Care, 2010, 33, 1186-1192.	8.6	286
13	Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segmentâ€Elevation Myocardial Infarction. Circulation, 2004, 109, 849-854.	1.6	280
14	Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. American Journal of Clinical Nutrition, 2010, 91, 940-949.	4.7	266
15	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	8.6	249
16	Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2643-2651.	3.6	244
17	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 864-876.	11.4	244
18	Increase in intranuclear nuclear factor κ B and decrease in inhibitor κ B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. American Journal of Clinical Nutrition, 2004, 79, 682-690.	4.7	224

#	ARTICLE	IF	CITATIONS
19	Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. <i>American Journal of Clinical Nutrition</i> , 2002, 75, 767-772.	4.7	222
20	Differential Effects of Cream, Glucose, and Orange Juice on Inflammation, Endotoxin, and the Expression of Toll-Like Receptor-4 and Suppressor of Cytokine Signaling-3. <i>Diabetes Care</i> , 2010, 33, 991-997.	8.6	214
21	Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 82-91.	8.6	214
22	Sitagliptin Exerts an Antiinflammatory Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3333-3341.	3.6	212
23	Exenatide Exerts a Potent Antiinflammatory Effect. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 198-207.	3.6	201
24	Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor- κ B, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4496-4501.	3.6	198
25	Suppression of Nuclear Factor- κ B and Stimulation of Inhibitor κ B by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1306-1312.	3.6	195
26	Carvedilol Inhibits Reactive Oxygen Species Generation by Leukocytes and Oxidative Damage to Amino Acids. <i>Circulation</i> , 2000, 101, 122-124.	1.6	193
27	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the Tj ETQq1 1 0.784314 rgBT /Overlo	8.6	190
28	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	8.6	177
29	Glucose Challenge Stimulates Reactive Oxygen Species (ROS) Generation by Leucocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2970-2973.	3.6	168
30	Increased Plasma Concentration of Macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in Mononuclear Cells in the Obese and the Suppressive Action of Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5043-5047.	3.6	167
31	Proinflammatory Effects of Glucose and Anti-Inflammatory Effect of Insulin: Relevance to Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2007, 99, 15-26.	1.6	162
32	Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 51-57.	4.7	148
33	Insulin as an Anti-Inflammatory and Antiatherogenic Modulator. <i>Journal of the American College of Cardiology</i> , 2009, 53, S14-S20.	2.8	144
34	Glucose ingestion induces an increase in intranuclear nuclear factor κ B, a fall in cellular inhibitor κ B, and an increase in tumor necrosis factor α messenger RNA by mononuclear cells in healthy human subjects. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1177-1185.	3.4	138
35	Antioxidant activity of carvedilol in cardiovascular disease. <i>Journal of Hypertension</i> , 2007, 25, 731-741.	0.5	137
36	Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin. <i>Endocrine Practice</i> , 2007, 13, 444-450.	2.1	128

#	ARTICLE	IF	CITATIONS
37	Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. <i>Experimental and Molecular Medicine</i> , 2010, 42, 245.	7.7	128
38	Insulin infusion in acute illness. <i>Journal of Clinical Investigation</i> , 2005, 115, 2069-2072.	8.2	127
39	Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. <i>Surgery</i> , 2012, 151, 587-593.	1.9	126
40	Nuclear Factor- κ B Suppressive and Inhibitor- κ B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action? <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3250-3256.	3.6	125
41	A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. <i>American Journal of Cardiology</i> , 2002, 90, 27-33.	1.6	124
42	Liraglutide as additional treatment for type 1 diabetes. <i>European Journal of Endocrinology</i> , 2011, 165, 77-84.	3.7	122
43	The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2422-2429.	3.6	120
44	Acute Modulation of Toll-Like Receptors by Insulin. <i>Diabetes Care</i> , 2008, 31, 1827-1831.	8.6	116
45	Testosterone Concentration in Young Patients With Diabetes. <i>Diabetes Care</i> , 2008, 31, 2013-2017.	8.6	113
46	Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1056-e1063.	3.6	113
47	Low Testosterone and High C-Reactive Protein Concentrations Predict Low Hematocrit in Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2289-2294.	8.6	110
48	Anti-inflammatory effects of insulin. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2007, 10, 511-517.	2.5	105
49	Tumor necrosis factor- α inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 487-491.	3.4	104
50	Low Estradiol Concentrations in Men With Subnormal Testosterone Concentrations and Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1854-1859.	8.6	104
51	Hypogonadotropic Hypogonadism in Men With Diabetes. <i>Diabetes Care</i> , 2018, 41, 1516-1525.	8.6	99
52	Vasodilatory Effects of Troglitazone Improve Blood Pressure at Rest and During Mental Stress in Type 2 Diabetes Mellitus. <i>Hypertension</i> , 1999, 34, 83-88.	2.7	97
53	Insulin Suppresses Plasma Concentration of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9. <i>Diabetes Care</i> , 2003, 26, 3310-3314.	8.6	96
54	RAPID COMMUNICATION: Inhibitory Effect of a Two Day Fast on Reactive Oxygen Species (ROS) Generation by Leucocytes and Plasma Ortho-Tyrosine and Meta-Tyrosine Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2899-2902.	3.6	85

#	ARTICLE	IF	CITATIONS
55	Insulin Inhibits the Pro-Inflammatory Transcription Factor Early Growth Response Gene-1 (Egr)-1 Expression in Mononuclear Cells (MNC) and Reduces Plasma Tissue Factor (TF) and Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1419-1422.	3.6	85
56	Endothelium, inflammation, and diabetes. <i>Current Diabetes Reports</i> , 2002, 2, 311-315.	4.2	83
57	Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. <i>Diabetes Care</i> , 2016, 39, 1027-1035.	8.6	80
58	Hypogonadotropic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome. <i>Current Molecular Medicine</i> , 2008, 8, 816-828.	1.3	79
59	Insulin Attenuates Norepinephrine- Induced Venoconstriction. <i>Hypertension</i> , 1995, 25, 779-784.	2.7	70
60	Endothelial Dysfunction, Inflammation and Diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 189-197.	5.7	69
61	Testosterone concentrations in young pubertal and postpubertal obese males. <i>Clinical Endocrinology</i> , 2013, 78, 593-599.	2.4	69
62	Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. <i>Angiogenesis</i> , 1998, 2, 93-104.	7.2	63
63	Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus. <i>Endocrine Practice</i> , 2013, 19, 963-967.	2.1	63
64	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Testosterone and Cardiovascular Risk. <i>Endocrine Practice</i> , 2015, 21, 1066-1073.	2.1	62
65	The Potential Therapeutic Role of Insulin in Acute Myocardial Infarction in Patients Admitted to Intensive Care and in Those With Unspecified Hyperglycemia. <i>Diabetes Care</i> , 2003, 26, 516-519.	8.6	59
66	Insulin Suppresses Endotoxin-Induced Oxidative, Nitrosative, and Inflammatory Stress in Humans. <i>Diabetes Care</i> , 2010, 33, 2416-2423.	8.6	58
67	Macronutrient-Mediated Inflammation and Oxidative Stress: Relevance to Insulin Resistance, Obesity, and Atherogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6118-6128.	3.6	58
68	Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3506-3515.	3.6	56
69	Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2055-2068.	4.4	55
70	Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 788-791.	3.4	51
71	Suppressive Effect of Insulin Infusion on Chemokines and Chemokine Receptors. <i>Diabetes Care</i> , 2010, 33, 1103-1108.	8.6	50
72	Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 498-506.	4.4	48

#	ARTICLE	IF	CITATIONS
73	Reduction in Inflammation and the Expression of Amyloid Precursor Protein and Other Proteins Related to Alzheimer's Disease following Gastric Bypass Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1197-E1201.	3.6	46
74	Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E810-E818.	3.5	46
75	Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: Reduction with weight loss. <i>Obesity</i> , 2014, 22, 356-362.	3.0	46
76	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 845-854.	11.4	46
77	Insulin as an anti-inflammatory and antiatherosclerotic hormone. <i>Clinical Cornerstone</i> , 2003, 5, S13-S20.	0.7	43
78	The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2007, 30, 1860-1861.	8.6	43
79	Hydrocortisone Suppresses Intranuclear Activator-Protein-1 (AP-1) Binding Activity in Mononuclear Cells and Plasma Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5988-5988.	3.6	41
80	Contrasting Testosterone Concentrations in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 1120-1122.	8.6	41
81	Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. <i>Diabetes Care</i> , 2019, 42, 1081-1087.	8.6	40
82	Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein. <i>Mayo Clinic Proceedings</i> , 2008, 83, 333-342.	3.0	39
83	Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1516-1526.	4.4	38
84	Anti-Inflammatory Effects of Insulin and the Pro-Inflammatory Effects of Glucose. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2006, 18, 293-301.	0.6	36
85	Increased $\text{I}\kappa\text{B}$ Expression and Diminished Nuclear $\text{NF-}\kappa\text{B}$ in Human Mononuclear Cells following Hydrocortisone Injection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3386-3389.	3.6	35
86	Endothelial dysfunction and hypertension in diabetes mellitus. <i>Medical Clinics of North America</i> , 2004, 88, 911-931.	2.5	35
87	Hypogonadotropic Hypogonadism in Men with Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2009, 121, 45-51.	2.0	35
88	Prediction of adverse outcomes by blood glucose level after endovascular therapy for acute ischemic stroke. <i>Journal of Neurosurgery</i> , 2011, 114, 1785-1799.	1.6	34
89	Distal small bowel bypass for weight regain after gastric bypass: safety and efficacy threshold occurs at 70% bypass. <i>Surgery for Obesity and Related Diseases</i> , 2015, 11, 1248-1255.	1.2	34
90	Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β -hydroxybutyrate levels in a phase IIa pilot study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 814-821.	4.4	34

#	ARTICLE	IF	CITATIONS
91	Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 18-28.	4.4	34
92	Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes. <i>Clinical Endocrinology</i> , 2016, 85, 772-780.	2.4	33
93	Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations. <i>Endocrine Practice</i> , 2011, 17, 192-200.	2.1	32
94	Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1742-1752.	4.4	32
95	Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. <i>European Journal of Endocrinology</i> , 2018, 178, 277-283.	3.7	31
96	Increase in Plasma Interleukin-10 Following Hydrocortisone Injection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1141-1144.	3.6	30
97	Insulin-induced vasodilatation of internal carotid artery. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 1470-1473.	3.4	30
98	Antiinflammatory and ROS Suppressive Effects of the Addition of Fiber to a High-Fat High-Calorie Meal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 858-869.	3.6	30
99	Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2029-2033.	4.4	30
100	Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease. <i>European Journal of Endocrinology</i> , 2015, 173, 359-366.	3.7	28
101	Vascular reactivity and thiazolidinediones. <i>American Journal of Medicine</i> , 2003, 115, 81-86.	1.5	27
102	RAPID COMMUNICATION: Inhibitory Effect of a Two Day Fast on Reactive Oxygen Species (ROS) Generation by Leucocytes and Plasma Ortho-Tyrosine and Meta-Tyrosine Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2899-2902.	3.6	24
103	Effect of Hyperglycemia and Insulin in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2007, 99, S12-S18.	1.6	23
104	Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2094-2102.	3.6	23
105	Testosterone Increases the Expression and Phosphorylation of AMP Kinase α in Men With Hypogonadism and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1169-1175.	3.6	23
106	Benefit/risk profile of dapagliflozin 5 mg in the ^{DEPICT} and ² trials in individuals with type 1 diabetes and body mass index ≥ 27 kg/m ² . <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2151-2160.	4.4	23
107	Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. <i>International Journal of Clinical Practice</i> , 2017, 71, e12937.	1.7	22
108	Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1306-1311.	4.4	22

#	ARTICLE	IF	CITATIONS
109	Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa049.	0.2	22
110	Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. <i>Journal of Diabetes and Its Complications</i> , 2004, 18, 91-102.	2.3	21
111	Intravenous Insulin Versus Conservative Management in Hypertriglyceridemia-Associated Acute Pancreatitis. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz019.	0.2	21
112	Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 549-560.	4.4	21
113	The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent. <i>Atherosclerosis</i> , 2015, 241, 111-120.	0.8	20
114	Thiazolidinediones improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2008, 22, 62-75.	2.3	19
115	Nonesterified Fatty Acids, Albumin, and Platelet Aggregation. <i>Diabetes</i> , 2015, 64, 703-705.	0.6	19
116	Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 729-733.	4.4	19
117	Insulin Suppresses the Expression of Amyloid Precursor Protein, Presenilins, and Glycogen Synthase Kinase-3 β in Peripheral Blood Mononuclear Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1783-1788.	3.6	18
118	Insulin Resistance and Endothelial Dysfunction in Atherosclerosis: Implications and Interventions. <i>Diabetes Technology and Therapeutics</i> , 2002, 4, 809-815.	4.4	17
119	Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus. <i>The Diabetes Educator</i> , 2005, 31, 843-848.	2.5	17
120	Adjunct therapies in treatment of type 1 diabetes. <i>Journal of Diabetes</i> , 2020, 12, 742-753.	1.8	17
121	Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E185-E191.	3.5	16
122	Relationship of Prostate -Specific Antigen to Age and Testosterone in Men With Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2008, 14, 1000-1005.	2.1	15
123	Oestradiol concentrations are not elevated in obesity-associated hypogonadotropic hypogonadism. <i>Clinical Endocrinology</i> , 2014, 80, 464-464.	2.4	14
124	Suppressive Effect of Insulin on the Gene Expression and Plasma Concentrations of Mediators of Asthmatic Inflammation. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-7.	2.3	14
125	Hydrocortisone Suppresses Intracellular Activator-Protein-1 (AP-1) Binding Activity in Mononuclear Cells and Plasma Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5988-5988.	3.6	14
126	Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. <i>Atherosclerosis</i> , 2017, 263, 278-286.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Exenatide Increases IL-1RA Concentration and Induces Nrf-2â€™Keap-1â€™Regulated Antioxidant Enzymes: Relevance to Î²-Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1180-1187.	3.6	13
128	Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1614-1623.	4.4	13
129	Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 137-142.	1.3	12
130	Addition of glucagonâ€™like peptideâ€™1 receptor agonist therapy to insulin in Câ€™peptideâ€™positive patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1054-1057.	4.4	12
131	Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. <i>Diabetes Care</i> , 2021, 44, 1929-1933.	8.6	12
132	Increase in Plasma Interleukin-10 Following Hydrocortisone Injection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1141-1144.	3.6	11
133	The metabolic syndrome: linking oxidative stress and inflammation to obesity, type 2 diabetes, and the syndrome. <i>Drug Development Research</i> , 2006, 67, 619-626.	2.9	10
134	Use of Insulin to Improve Glycemic Control in Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 241-251.	2.6	10
135	Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone. <i>Journal of the Endocrine Society</i> , 2019, 3, 1617-1630.	0.2	10
136	Anti-inflammatory effects of insulin and pro-inflammatory effects of glucose: relevance to the management of acute myocardial infarction and other acute coronary syndromes. <i>Reviews in Cardiovascular Medicine</i> , 2006, 7 Suppl 2, S25-34.	1.4	9
137	Deaths and Cardiovascular Events in Men Receiving Testosterone. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 964.	7.4	8
138	Incretins: <sc>B</sc>eyond type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 59-67.	4.4	8
139	Semaglutide in Cystic Fibrosis-Related Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2341-2344.	3.6	8
140	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	1.0	7
141	4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo. <i>Endocrine Connections</i> , 2021, 10, 861-872.	1.9	6
142	Acute effects of insulin on skeletal muscle growth and differentiation genes in men with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2019, 181, K55-K59.	3.7	6
143	Rosiglitazone, thiazolidinediones and atherosclerosis. <i>Atherosclerosis</i> , 2010, 211, 384-385.	0.8	5
144	Macronutrient intake, insulin secretion, oxidative stress & inflammation: Clinico-pathological implications. <i>Indian Journal of Medical Research</i> , 2016, 144, 645.	1.0	5

#	ARTICLE	IF	CITATIONS
145	Intensive Glucose Control in Hyperglycemic Patients With Acute Coronary Syndromes. <i>JAMA Internal Medicine</i> , 2013, 173, 1905.	5.1	4
146	Intranasal Insulin Administration Does Not Affect LH Concentrations in Men with Diabetes. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	4
147	Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): A Novel Way to Explain the Anti-oxidant Paradox. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 155-159.	1.3	3
148	Anti-inflammatory and antiatherogenic effects of insulin. <i>Insulin</i> , 2006, 1, S11-S17.	0.2	3
149	A Novel Antihypertensive Effect of Exenatide, a GLP-1 Agonist. <i>American Journal of Hypertension</i> , 2010, 23, 228-228.	2.0	3
150	Glycaemia and insulin after acute myocardial infarction. <i>Nature Reviews Endocrinology</i> , 2014, 10, 448-450.	9.6	3
151	Vascular reactivity in diabetes mellitus. <i>Endocrinología Y Nutrición: Órgano De La Sociedad Española De Endocrinología Y Nutrición</i> , 2009, 56 Suppl 4, 12-4.	0.8	3
152	Potential use of insulin as an anti-inflammatory drug. <i>Drug Development Research</i> , 2008, 69, 101-110.	2.9	2
153	Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 244-245.	3.3	2
154	Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. <i>Diabetes Care</i> 2012;35:2076-2082. <i>Diabetes Care</i> , 2013, 36, e80-e80.	8.6	2
155	Comment on Sarkar et al. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. <i>Diabetes Care</i> 2014;37:666-670. <i>Diabetes Care</i> , 2014, 37, e218-e218.	8.6	2
156	Targeting AMP Kinase in Myeloid Cells to Reduce Atherosclerosis. <i>Diabetes</i> , 2016, 65, 1493-1495.	0.6	2
157	Letter to the Editor: "Long-Term Testosterone Administration on Insulin Sensitivity in Older Men With Low or Low-Normal Testosterone Levels". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2069-2070.	3.6	2
158	Comment on Vandal et al. Insulin Reverses the High-Fat Diet-Induced Increase in Brain A β 2 and Improves Memory in an Animal Model of Alzheimer Disease. <i>Diabetes</i> 2014;63:4291-4301. <i>Diabetes</i> , 2015, 64, e17-e17.	0.6	1
159	Changes in Coronary Artery Plaque With Testosterone Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2450.	7.4	1
160	Macronutrient intake and oxidative stress/inflammation in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 247-248.	2.3	1
161	Liraglutide and systolic blood pressure. <i>Journal of Clinical Hypertension</i> , 2019, 21, 116-117.	2.0	1
162	Narcolepsy, depression, and severe flushing in an obese man. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1824-1826.	0.5	1

#	ARTICLE	IF	CITATIONS
163	274-LB: The Anti-inflammatory Effects of Insulin and Hydrocortisone Combination in Obese Subjects. Diabetes, 2019, 68, 274-LB.	0.6	1
164	Do Thiazolidinediones Exert Their Insulin-Sensitizing Effect Through the Suppression of Free Fatty Acids?. Metabolic Syndrome and Related Disorders, 2004, 2, 287-289.	1.3	0
165	Oxidative Inflammatory Stress in Obesity and Diabetes. , 2006, , 307-316.		0
166	Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary. Clinical Diabetes, 2020, 38, 324-327.	2.2	0